Long-term steroid therapy in children: Is adjunct therapy relevant in nephrotic syndrome?;Corticothérapie prolongée chez l'enfant : quelle place pour un traitement adjuvant dans le syndrome néphrotique ?

Archives de Pediatrie

Volumn 15, Issue 11, 2008, Pages 1685-1692

  Bacchetta, J ^a   Harambat, J ^a,b   Cochat, P ^a  

^a HOSPICES CIVILS DE LYON   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; COLECALCIFEROL; GLUCOCORTICOID; GROWTH HORMONE; HUMAN GROWTH HORMONE; PAMIDRONIC ACID; PLACEBO; PREDNISOLONE; STEROID; VITAMIN D;

BONE DISEASE; CALCIUM INTAKE; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; HUMAN; LONG TERM CARE; NEPHROTIC SYNDROME; PHYSICAL ACTIVITY; PROPHYLAXIS; RISK FACTOR; SHORT SURVEY; SUN EXPOSURE; SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION;

ADRENAL CORTEX HORMONES; BONE AND BONES; BONE DISEASES; CALCIUM; CHEMOTHERAPY, ADJUVANT; CHILD; HUMANS; NEPHROTIC SYNDROME; PHOSPHORUS; TIME FACTORS;

EID: 55349124551     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2008.08.020     Document Type: Short Survey

References (48)

1. Travis L.B., Chesney R., McEnery P., et al. Growth and glucocorticoids in children with kidney disease. Kidney Int 14 (1978) 365-368
2. Leonard M.B. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics 119 Suppl. 2 (2007) S166-S174
3. Freundlich M., Jofe M., Goodman W.G., et al. Bone histology in steroid-treated children with non-azotemic nephrotic syndrome. Pediatr Nephrol 19 (2004) 400-407
4. Weng F.L., Shults J., Herskovitz R.M., et al. Vitamin D insufficiency in steroid-sensitive nephrotic syndrome in remission. Pediatr Nephrol 20 (2005) 56-63
5. Freundlich M., Bourgoignie J.J., Zilleruelo G., et al. Calcium and vitamin D metabolism in children with nephrotic syndrome. J Pediatr 108 (1986) 383-387
6. Grymonprez A., Proesmans W., Van Dyck M.J., et al. Vitamin D metabolites in childhood nephrotic syndrome. Pediatr Nephrol 9 (1995) 278-281
7. Elder G.J. Nephrotic syndrome: don't forget the bones!. Nephrology 13 (2008) 43-44
8. Leonard M.B., Shults J., Elliott D.M., et al. Interpretation of whole body dual energy X-ray absorptiometry measures in children: comparison with peripheral quantitative computed tomography. Bone 34 (2004) 1044-1052
9. Polito C., La Manna A., Todisco N., et al. Bone mineral content in nephrotic children on long-term, alternate-day prednisone therapy. Clin Pediatr (Phila) 34 (1995) 234-236
10. Leonard M.B., Feldman H.I., Shults J., et al. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 351 (2004) 868-875
11. Gulati S., Godbole M., Singh U., et al. Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease?. Am J Kidney Dis 41 (2003) 1163-1169
12. Gulati S., and Gulati K. Bone disease in nephrotic syndrome-prevention is better than cure. Pediatr Nephrol 20 (2005) 111-112
13. Hegarty J., Mughal M.Z., Adams J., et al. Reduced bone mineral density in adults treated with high-dose corticosteroids for childhood nephrotic syndrome. Kidney Int 68 (2005) 2304-2309
14. van Staa T.P., Leufkens H.G., and Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13 (2002) 777-787
15. Ward L.M. Osteoporosis due to glucocorticoid use in children with chronic illness. Horm Res 64 (2005) 209-221
16. Nilsson O., Marino R., De Luca F., et al. Endocrine regulation of the growth plate. Horm Res 64 (2005) 157-165
17. Fouque-Aubert A., and Chapurlat R. Influence of RANKL inhibition on immune system in the treatment of bone diseases. Joint Bone Spine 75 (2008) 5-10
18. Hochberg Z. Mechanisms of steroid impairment of growth. Horm Res 58 Suppl. 1 (2002) 33-38
19. Perez A.V., Picotto G., Carpentieri A.R., et al. Minireview on regulation of intestinal calcium absorption. Emphasis on molecular mechanisms of transcellular pathway. Digestion 77 (2008) 22-34
20. Ferrari P., Bianchetti M.G., Sansonnens A., et al. Modulation of renal calcium handling by 11 beta-hydroxysteroid dehydrogenase type 2. J Am Soc Nephrol 13 (2002) 2540-2546
21. Bianchi M.L. Glucorticoids and bone: some general remarks and some special observations in pediatric patients. Calcif Tissue Int 70 (2002) 384-390
22. Gafni R.I., McCarthy E.F., Hatcher T., et al. Recovery from osteoporosis through skeletal growth: early bone mass acquisition has little effect on adult bone density. FASEB J 16 (2002) 736-738
23. Bachrach L.K. Measuring bone mass in children: can we really do it?. Horm Res 65 Suppl. 2 (2006) 11-16
24. NIH. Osteoporosis: prevention, diagnosis and therapy. In: http://consensus.nih.gov/2000/2000Oteoporosis111html.htm; 2000. (Consulté en septembre 2007).
25. Bak M., Serdaroglu E., and Guclu R. Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome. Pediatr Nephrol 21 (2006) 350-354
26. Bechtold S., Ripperger P., Muhlbayer D., et al. GH therapy in juvenile chronic arthritis: results of a two-year controlled study on growth and bone. J Clin Endocrinol Metab 86 (2001) 5737-5744
27. Simon D., Prieur A.M., Quartier P., et al. Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. J Clin Endocrinol Metab 92 (2007) 2567-2573
28. Grote F.K., Van Suijlekom-Smit L.W., Mul D., et al. Growth hormone treatment in children with rheumatic disease, corticosteroid induced growth retardation, and osteopenia. Arch Dis Child 91 (2006) 56-60
29. Lovell D.J., Glass D., Ranz J., et al. A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis. Arthritis Rheum 54 (2006) 2235-2242
30. El-Husseini A.A., El-Agroudy A.E., El-Sayed M., et al. A prospective randomized study for the treatment of bone loss with vitamin D during kidney transplantation in children and adolescents. Am J Transplant 4 (2004) 2052-2057
31. Rooney M., Davies U.M., Reeve J.P., et al. Bone mineral content and bone mineral metabolism: changes after growth hormone treatment in juvenile chronic arthritis. J Rheumatol 27 (2000) 1073-1081
32. Kim S.D., and Cho B.S. Pamidronate therapy for preventing steroid-induced osteoporosis in children with nephropathy. Nephron Clin Pract 102 (2006) c81-c87
33. Brown J.J., and Zacharin M.R. Attempted randomized controlled trial of pamidronate versus calcium and calcitriol supplements for management of steroid-induced osteoporosis in children and adolescents. J Paediatr Child Health 41 (2005) 580-582
34. El-Husseini A.A., El-Agroudy A.E., El-Sayed M.F., et al. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr Transplant 8 (2004) 357-361
35. Gulati S., Sharma R.K., Gulati K., et al. Longitudinal follow-up of bone mineral density in children with nephrotic syndrome and the role of calcium and vitamin D supplements. Nephrol Dial Transplant 20 (2005) 1598-1603
36. Loke K.Y., Yap H.K., Zhou X., et al. Efficacy and safety of one year of growth hormone therapy in steroid-dependent nephrotic syndrome. J Pediatr 130 (1997) 793-799
37. Nishioka T., Kurayama H., Yasuda T., et al. Nasal administration of salmon calcitonin for prevention of glucocorticoid-induced osteoporosis in children with nephrosis. J Pediatr 118 (1991) 703-707
38. Homik J., Suarez-Almazor M.E., Shea B., et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev (2000) CD000952
39. Mauras N. Growth hormone therapy in the glucocorticosteroid-dependent child: metabolic and linear growth effects. Horm Res 56 Suppl. 1 (2001) 13-18
40. Palmer S.C., Strippoli G.F., and McGregor D.O. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis 45 (2005) 638-649
41. Mitterbauer C., Schwarz C., Haas M., et al. Effects of bisphosphonates on bone loss in the first year after renal transplantation - a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 21 (2006) 2275-2281
42. Bianchi M.L., Cimaz R., Bardare M., et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 43 (2000) 1960-1966
43. Cranney A., Welch V., Adachi J.D., et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev (2000) CD001983
44. Valta H., Lahdenne P., Jalanko H., et al. Bone health and growth in glucocorticoid-treated patients with juvenile idiopathic arthritis. J Rheumatol 34 (2007) 831-836
45. Ferraris J.R., Pasqualini T., Alonso G., et al. Effects of deflazacort versus methylprednisone: a randomized study in kidney transplant patients. Pediatr Nephrol 22 (2007) 734-741
46. Hodson E.M., Knight J.F., Willis N.S., et al. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev (2005) CD001533
47. Ulinski T., Dubourg L., Said M.H., et al. Switch from cyclosporine A to mycophenolate mofetil in nephrotic children. Pediatr Nephrol 20 (2005) 482-485
48. Binkovitz L.A., and Henwood M.J. Pediatric DXA: technique and interpretation. Pediatr Radiol 37 (2007) 21-31